May 02, 2023 7:00am EDT Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
Apr 24, 2023 7:00am EDT Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
Apr 10, 2023 7:00am EDT Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
Mar 16, 2023 7:00am EDT Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
Mar 13, 2023 7:00am EDT Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
Feb 14, 2023 7:00am EST Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
Jan 24, 2023 7:00am EST Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
Jan 11, 2023 9:04am EST Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
Jan 10, 2023 7:00am EST Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
